The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer

Autor: Malik Ejder Yildirim, Hasan Kilicgun, Serpil Erşan, Hande Küçük Kurtulgan, Savas Karakus, Sevtap Bakir
Přispěvatelé: [Yildirim, Malik Ejder -- Kurtulgan, Hande Kucuk] Cumhuriyet Univ, Dept Med Genet, Fac Med, TR-58140 Sivas, Turkey -- [Karakus, Savas] Cumhuriyet Univ, Dept Obstet & Gynecol, Fac Med, TR-58140 Sivas, Turkey -- [Kilicgun, Hasan] Erzincan Univ, Dept Nutr & Dietet, Fac Hlth Sci, TR-24030 Erzincan, Turkey -- [Ersan, Serpil -- Bakir, Sevtap] Cumhuriyet Univ, Dept Med Biochem, Fac Med, TR-58140 Sivas, Turkey, Kurtulgan, Hande Kucuk -- 0000-0001-9172-3244, Yildirim, Malik Ejder -- 0000-0003-4386-1583, ERSAN, Serpil -- 0000-0002-8968-4044
Rok vydání: 2016
Předmět:
Adult
Genotype
medicine.medical_treatment
030204 cardiovascular system & hematology
Biochemistry
Tissue plasminogen activator
Polymorphism
Single Nucleotide
PAI-1 4G/5G polymorphism
Andrology
03 medical and health sciences
0302 clinical medicine
Endometrial cancer
Polymorphism (computer science)
Fibrinolysis
Grades
Plasminogen Activator Inhibitor 1
Genetics
medicine
Carcinoma
Humans
Genetic Predisposition to Disease
Promoter Regions
Genetic
Molecular Biology
Allele frequency
Ecology
Evolution
Behavior and Systematics
Genetic Association Studies
Aged
Serine protease
biology
General Medicine
Middle Aged
medicine.disease
PAI-1 levels
Endometrial Neoplasms
Gene Expression Regulation
Neoplastic
030220 oncology & carcinogenesis
Immunology
biology.protein
Female
Gene polymorphism
Neoplasm Grading
medicine.drug
Zdroj: Biochemical genetics. 55(4)
ISSN: 1573-4927
Popis: WOS: 000405778000004
PubMed ID: 28303356
Plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor (Serpine 1), and it inhibits both tissue plasminogen activator and urokinase plasminogen activator which are important in fibrinolysis. We aimed to find whether there is a possible association between PAI-1 level, PAI-1 4G/5G polymorphism, and endometrial cancer. PAI-1 levels in peripheral blood were determined in 82 patients with endometrial carcinoma and 76 female healthy controls using an enzyme-linked immunoassay (ELISA). Then, the genomic DNA was extracted and screened by reverse hybridization procedure (Strip assay) to detect PAI 1 4G/5G polymorphism. The levels of PAI-1 in the patients were higher statistically in comparison to controls (P < 0.001). The distribution of PAI-1 4G/5G polymorphism was quite different between patients and controls (P = 0.008), and 4G allelic frequency was significantly higher in the patients of endometrial cancer than in controls (P = 0.026). We found significant difference between Grade 1 and Grade 2+3 patients in terms of the PAI-1 levels (P = 0.047). There was no association between PAI-1 4G/5G polymorphism and the grades of endometrial cancer (P = 0.993). Our data suggest that the level of PAI-1 and PAI-1 4G/5G gene polymorphism are effective in the formation of endometrial cancer. PAI-1 levels are also associated with the grades of endometrial cancer.
Databáze: OpenAIRE
Externí odkaz: